Correspondence 0001193125-23-122153 from Taysha Gene Therapies, Inc. (TSHA) (CIK 0001806310) (TSHA)
Taysha Gene Therapies, Inc. (TSHA) (CIK 0001806310)
Date: April 27, 2023 · CIK: 0001806310 · Accession: 0001193125-23-122153
AI Filing Summary & Sentiment
File numbers found in text: 333-271144
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 27, 2023 VIA EDGAR Joshua Gorsky U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Taysha Gene Therapies, Inc. Registration Statement on Form S-3 (File No. 333-271144) Request for Acceleration of Effective Date Acceleration Request Requested Date: Monday, May 1, 2023 Requested Time: 4:00 p.m. Eastern Time Dear Mr. Gorsky: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-271144) (the “Registration Statement”) to become effective on Monday, May 1, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones of Cooley LLP, counsel to the Registrant, at (202) 728-7087, or in her absence, Paul Alexander, at (202) 776-2118. Very truly yours, TAYSHA GENE THERAPIES, INC. By: /s/ Sean P. Nolan Sean P. Nolan Chief Executive Officer